Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some core labeling elements are consistent (indication age range, viloxazine/SNRI mechanism, suicidality warning), but multiple claims are unsupported or partially supported due to missing label details in the provided excerpts (approval timing, non-stimulant characterization, dopamine claim, effectiveness vs placebo, common adverse reaction list, once-daily dosing frequency, boxed-warning format, and specific monitoring wording).
Category Scores
Accurate Statements
Qelbree is a selective norepinephrine reuptake inhibitor (SNRI).
Section 11 (contains viloxazine; described as selective norepinephrine reuptake inhibitor) and Section 12.1 (thought to inhibit reuptake of norepinephrine).
The active ingredient in Qelbree is viloxazine.
Section 11 (Qelbree contains viloxazine).
Qelbree carries a risk of suicidal thoughts and behaviors.
Section 6 and WARNING (higher rates of suicidal thoughts/behavior vs placebo; monitor all Qelbree-treated patients).
Unsupported Statements
Qelbree received FDA approval in December 2021.
No approval-date information is present in the provided label sections.
Qelbree is a non-stimulant medication used to treat ADHD.
The provided excerpts do not explicitly describe Qelbree as a non-stimulant.
Qelbree works by increasing levels of norepinephrine in the brain.
Section 12.1 describes inhibiting norepinephrine reuptake, but the provided text does not explicitly state it increases norepinephrine levels in the brain.
Qelbree does not have a direct effect on dopamine levels.
No dopamine-related statements are present in the provided label excerpts.
Following its FDA approval in December 2021, Qelbree became available for prescription in the United States.
No market availability/implementation timing information is present in the provided label sections.
Qelbree is manufactured by Supernus Pharmaceuticals.
No manufacturer information is present in the provided label excerpts.
In clinical trials, Qelbree was effective in reducing ADHD symptoms compared to placebo.
Section 14 is only listed as present without provided content; the effectiveness statement is not supported by the provided excerpts.
Common side effects of Qelbree include somnolence (sleepiness), decreased appetite, insomnia, nausea and vomiting, fatigue, and dizziness.
The provided excerpts mention somnolence and fatigue as serious adverse reactions, but do not support the full enumerated 'common side effects' list (decreased appetite, insomnia, nausea/vomiting, dizziness).
Dosing for Qelbree typically starts low and is gradually increased based on individual response and tolerance.
No titration/dosing strategy details are present in the provided label excerpts.
Qelbree carries a boxed warning regarding suicidal thoughts and behaviors.
The provided excerpts include a WARNING section for suicidality but do not explicitly confirm it is a 'boxed warning' in the excerpts provided.
Contradictions
Important Omissions
Administration detail that capsules should not be cut, crushed, or chewed; option to open capsule and sprinkle contents with timing constraints for pudding or applesauce.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Multiple safety-related claims are partially supported or unsupported (e.g., 'common side effects' list not supported; potential overstatement of whether the suicidality warning is boxed; monitoring wording not fully aligned with excerpted label language).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several key claims are not supported by the provided label excerpts (approval timing/availability, non-stimulant/dopamine assertions, placebo effectiveness, common adverse reaction list, dosing frequency/titration details, and boxed-warning confirmation).
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label sections (Section 1 indication age range, Section 11 SNRI/viloxazine content, Section 2.3 oral administration 'with or without food' and capsule handling, Section 6/WARNING suicidality monitoring language). Avoid specifying approval dates, manufacturing, effectiveness comparisons, dopamine statements, and unverified 'common side effects' or boxed-warning format unless directly present in the provided label text.